Digital treatments for opioids and other substance use disorders (DIGITS) in primary care: A hybrid type-III implementation trial
初级保健中阿片类药物和其他物质使用障碍 (DIGITS) 的数字治疗:混合 III 型实施试验
基本信息
- 批准号:10560538
- 负责人:
- 金额:$ 59.63万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-04-01 至 2025-02-28
- 项目状态:未结题
- 来源:
- 关键词:AbstinenceAcademyAddressAdoptedAdoptionBehavioralBuprenorphineCaringCellular PhoneClassificationClinicCognitiveCognitive TherapyCollaborationsDataDedicationsDoseDrug Use DisorderEducationEffectivenessEnsureEpidemicFDA approvedFaceHealth systemHealthcareHumanHybridsIndividualInterventionKnowledgeLaboratoriesLearningLifeLiteratureMedicalMedicineMethodsModelingObservational StudyOpioidPatientsPearPersonsPopulationPrimary CareRandomizedRandomized, Controlled TrialsResearch DesignResearch PersonnelRunningSubstance Use DisorderSymptomsSystemTestingTherapeuticTractionUnited States Food and Drug AdministrationVisitWashingtonWorld Healthalcohol use disorderbehavioral healthbuprenorphine treatmentcare systemscompare effectivenesscomputerizedcostcost effectivenessdesigndigitaldigital healthdigital treatmenteffective interventioneffective therapyeffectiveness/implementation hybridevidence baseformative assessmentimplementation barriersimplementation costimplementation scienceimplementation strategyimplementation trialimprovedinnovationinstrumentnovel strategiesopioid mortalityopioid use disorderpopulation basedprimary care clinicprimary care patientprimary care teampsychosocialscreeningsmartphone applicationsubstance usesuccess
项目摘要
PROJECT SUMMARY
The proposed study addresses a critical knowledge gap: How to best implement digital treatments for
opioids and other substance use disorders (SUDs) in primary care (PC). In 2017, the US Food and Drug
Administration approved the first ever digital therapeutic for any medical condition. The therapeutic is reSET, a
smartphone-based version of the Therapeutic Educational System, which is a computerized cognitive-
behavioral treatment for SUDs. We will study implementation of reSET into PC to potentially improve care for
people with SUDs, and as a model for how to sustainably implement digital treatments into real-world
healthcare. Digital treatments could extend the reach of SUD therapy to more people and could address the
lack of access to psychosocial treatment, a significant barrier to buprenorphine prescribing (a life-saving
treatment for opioid use disorders [OUD]) in PC. A prior implementation trial found that a digital SUD treatment
in PC was not sustained in part because of workflow and cost burdens so our study design and analytic plan
focus on these issues. Our delivery system partners in Kaiser Permanente Washington are committed to
collaborating with us to study strategies for implementing reSET in 25 PC clinics in Washington State and to
address prior implementation challenges documented in the literature. After piloting in 2 clinics, we will
randomize 23 clinics in a 2x2 factorial design to four approaches: (1) “standard implementation,” which is an
evidence-based implementation strategy previously used by our delivery system partners; (2) “standard
implementation with external facilitation,” a clinician-facing implementation strategy; (3) “standard
implementation with patient coach,” a patient-facing implementation strategy using medical assistants to
support patient adoption and engagement; and (4) “standard implementation with both.” These implementation
strategies have some evidence in PC, but their impact on real-world implementation of a digital treatment has
not been evaluated. Specific Aims are to (1) Estimate the effect of clinician-facing (external facilitation) and
patient-facing (patient coach) implementation strategies in increasing the reach and fidelity of a digital SUD
treatment in PC clinics, and (2) compare the population-level cost-effectiveness of each implementation
strategy in increasing reach, fidelity, and abstinence by patients. IMPACT: Researchers and health systems do
not know how to reach large numbers of patients with OUDs and other SUDs. Digital treatments are
promising, but health systems lack evidence to guide implementation of digital therapies. This study will
estimate and compare the effectiveness of clinician-facing and patient-facing implementation strategies,
providing health system leaders with data on how to best implement digital treatments.
项目概要
拟议的研究解决了一个关键的知识差距:如何最好地实施数字治疗
初级保健 (PC) 中的阿片类药物和其他物质使用障碍 (SUD)。 2017年,美国食品药品监督管理局
政府批准了有史以来第一个针对任何医疗状况的数字疗法。治疗方法是reSET,
基于智能手机的治疗教育系统版本,这是一种计算机化的认知-
SUD 的行为治疗。我们将研究在 PC 中实施 reSET,以潜在地改善对患者的护理
患有 SUD 的人,并作为如何在现实世界中可持续实施数字治疗的模型
卫生保健。数字化治疗可以将 SUD 疗法的覆盖范围扩大到更多人,并可以解决以下问题:
缺乏获得心理社会治疗的机会,这是开具丁丙诺啡处方(一种挽救生命的药物)的一个重大障碍
PC 中阿片类药物使用障碍 [OUD] 的治疗。先前的实施试验发现,数字 SUD 治疗
由于工作流程和成本负担,PC 中的研究未能持续,因此我们的研究设计和分析计划
关注这些问题。我们在华盛顿凯撒医疗机构的交付系统合作伙伴致力于
与我们合作研究在华盛顿州 25 家 PC 诊所实施 reSET 的策略,并
解决文献中记录的先前实施挑战。在 2 家诊所试点后,我们将
采用 2x2 析因设计将 23 个诊所随机分为四种方法:(1) “标准实施”,这是一种
我们的交付系统合作伙伴之前使用的基于证据的实施策略; (2)“标准
外部促进的实施,”面向临床医生的实施策略;(3)“标准
与患者教练一起实施”,这是一种面向患者的实施策略,使用医疗助理来
支持患者采用和参与; (4)“两者的标准实施”。这些实现
策略在 PC 上有一些证据,但它们对现实世界中数字治疗实施的影响
没有被评估。具体目标是 (1) 评估面向临床医生(外部促进)和
面向患者(患者教练)的实施策略,以提高数字 SUD 的覆盖范围和保真度
PC 诊所的治疗,以及 (2) 比较每种实施方案的人群水平成本效益
增加患者的覆盖范围、忠诚度和禁欲的策略。影响:研究人员和卫生系统确实
不知道如何接触大量 OUD 和其他 SUD 患者。数字治疗是
前景广阔,但卫生系统缺乏证据来指导数字疗法的实施。这项研究将
评估并比较面向临床医生和面向患者的实施策略的有效性,
为卫生系统领导者提供有关如何最好地实施数字治疗的数据。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Joseph Edwin Glass其他文献
Joseph Edwin Glass的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Joseph Edwin Glass', 18)}}的其他基金
C-DIAS RP3: Scaling-out app-based treatments: a multi-level strategy to promote equity across primary care patients with substance use
C-DIAS RP3:扩展基于应用程序的治疗:促进初级保健药物使用患者公平的多层次策略
- 批准号:
10493961 - 财政年份:2022
- 资助金额:
$ 59.63万 - 项目类别:
C-DIAS RP3: Scaling-out app-based treatments: a multi-level strategy to promote equity across primary care patients with substance use
C-DIAS RP3:扩展基于应用程序的治疗:促进初级保健药物使用患者公平的多层次策略
- 批准号:
10668496 - 财政年份:2022
- 资助金额:
$ 59.63万 - 项目类别:
Multi-level Influences of Alcohol Based Quality and Outcome Measures
酒精质量的多层次影响和结果测量
- 批准号:
10704144 - 财政年份:2022
- 资助金额:
$ 59.63万 - 项目类别:
Multi-level Influences of Alcohol Based Quality and Outcome Measures
酒精质量的多层次影响和结果测量
- 批准号:
10590820 - 财政年份:2022
- 资助金额:
$ 59.63万 - 项目类别:
Digital treatments for opioids and other substance use disorders (DIGITS) in primary care: A hybrid type-III implementation trial
初级保健中阿片类药物和其他物质使用障碍 (DIGITS) 的数字治疗:混合 III 型实施试验
- 批准号:
10092143 - 财政年份:2019
- 资助金额:
$ 59.63万 - 项目类别:
Digital treatments for opioids and other substance use disorders (DIGITS) in primary care: A hybrid type-III implementation trial
初级保健中阿片类药物和其他物质使用障碍 (DIGITS) 的数字治疗:混合 III 型实施试验
- 批准号:
10349443 - 财政年份:2019
- 资助金额:
$ 59.63万 - 项目类别:
Digital treatments for opioids and other substance use disorders (DIGITS) in primary care: A hybrid type-III implementation trial
初级保健中阿片类药物和其他物质使用障碍 (DIGITS) 的数字治疗:混合 III 型实施试验
- 批准号:
9902391 - 财政年份:2019
- 资助金额:
$ 59.63万 - 项目类别:
Digital treatments for opioids and other substance use disorders (DIGITS) in primary care: Observational Analysis of Adaptions to the Intervention
初级保健中阿片类药物和其他物质使用障碍 (DIGITS) 的数字化治疗:干预措施适应的观察分析
- 批准号:
10652751 - 财政年份:2019
- 资助金额:
$ 59.63万 - 项目类别:
Decreasing the Engagement Gap for Addiction Treatment in Primary Care
缩小初级保健中成瘾治疗的参与差距
- 批准号:
9981556 - 财政年份:2017
- 资助金额:
$ 59.63万 - 项目类别:
Decreasing the Engagement Gap for Addiction Treatment in Primary Care
缩小初级保健中成瘾治疗的参与差距
- 批准号:
10222485 - 财政年份:2017
- 资助金额:
$ 59.63万 - 项目类别:
相似海外基金
The European Hydrogen Academy (HyAcademy.EU)
欧洲氢学院 (HyAcademy.EU)
- 批准号:
10110448 - 财政年份:2024
- 资助金额:
$ 59.63万 - 项目类别:
EU-Funded
REU Site: Summer Academy in Sustainable Manufacturing
REU 网站:可持续制造夏季学院
- 批准号:
2348993 - 财政年份:2024
- 资助金额:
$ 59.63万 - 项目类别:
Standard Grant
GP-UP Ocean Research College Academy Engagement in Authentic Geoscience Learning Ecosystems (ORCA-EAGLE)
GP-UP 海洋研究学院学院参与真实的地球科学学习生态系统 (ORCA-EAGLE)
- 批准号:
2326962 - 财政年份:2024
- 资助金额:
$ 59.63万 - 项目类别:
Standard Grant
HyAcademy.EU: The European Hydrogen Academy
HyAcademy.EU:欧洲氢学院
- 批准号:
10101978 - 财政年份:2024
- 资助金额:
$ 59.63万 - 项目类别:
EU-Funded
Baycrest Academy for Research and Education Summer Program in Aging (SPA): Strengthening research competencies, cultivating empathy, building interprofessional networks and skills, and fostering innovation among the next generation of healthcare workers t
Baycrest Academy for Research and Education Summer Program in Aging (SPA):加强研究能力,培养同理心,建立跨专业网络和技能,并促进下一代医疗保健工作者的创新
- 批准号:
498310 - 财政年份:2024
- 资助金额:
$ 59.63万 - 项目类别:
Operating Grants
Conference: Cyberinfrastructure Leadership Academy: Team Science and Grand Challenges
会议:网络基础设施领导学院:团队科学和重大挑战
- 批准号:
2414440 - 财政年份:2024
- 资助金额:
$ 59.63万 - 项目类别:
Standard Grant
Travel: NSF Student Travel Grant for 2024 Academy of Management Annual Meeting (AOM)
旅行:2024 年管理学院年会 (AOM) 的 NSF 学生旅行补助金
- 批准号:
2420866 - 财政年份:2024
- 资助金额:
$ 59.63万 - 项目类别:
Standard Grant
Semiconductor Higher Technical Skills Academy Wales: Recruitment, Retention & Upskilling
威尔士半导体高等技术技能学院:招聘、保留
- 批准号:
10076049 - 财政年份:2023
- 资助金额:
$ 59.63万 - 项目类别:
Collaborative R&D
Simulation Academy at Yale: Youth Entering Science (SAY-YES!)
耶鲁大学模拟学院:青年进入科学(说是!)
- 批准号:
10663646 - 财政年份:2023
- 资助金额:
$ 59.63万 - 项目类别:
Collaborative Research: GP-GO: Climate Leaders Academy: a professional development opportunity in the geosciences
合作研究:GP-GO:气候领袖学院:地球科学领域的专业发展机会
- 批准号:
2232215 - 财政年份:2023
- 资助金额:
$ 59.63万 - 项目类别:
Continuing Grant